Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma
NCT06034977
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
120
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
ADI-PEG20
Sponsor
Chang Gung Memorial Hospital